The Sant’Orsola-Malpighi Polyclinic is a university and public hospital. The Polyclinc is the largest hospital in Italy, and the first of the four public hospitals of the city of Bologna. The Polyclinic has approximately 1,535 beds and 5,153 employees.

There are 1,535 beds in Policlinico S. Orsola Malpighi.

During the past decade, Policlinico S. Orsola Malpighi conducted 436 clinical trials. In the 10-year time frame, 436 clinical trials started and 155 clinical trials were completed, i.e. on average, 35.6% percent of trials that started reached the finish line to date. In the past 5 years, 199 clinical trials started and 108 clinical trials were completed. i.e. 54.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Policlinico S. Orsola Malpighi" #1 sponsor was "Celgene" with 46 trials, followed by "IRCCS Azienda Ospedaliero-Universitaria di Bologna" with 39 trials sponsored, "University of Bologna" with 26 trials sponsored, "Janssen Research & Development, LLC" with 24 trials sponsored and "Hoffmann-La Roche" with 24 trials sponsored. Other sponsors include 464 different institutions and companies that sponsored additional 236 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Policlinico S. Orsola Malpighi" #1 collaborator was "AstraZeneca" with 6 trials as a collaborator, "Istituto Di Ricerche Farmacologiche Mario Negri" with 5 trials as a collaborator, "Merck Sharp & Dohme LLC" with 5 trials as a collaborator, "University of Bologna" with 5 trials as a collaborator and "AbbVie" with 4 trials as a collaborator. Other collaborators include 307 different institutions and companies that were collaborators in the rest 279 trials.

According to Clinical.Site data, the most researched conditions in "Policlinico S. Orsola Malpighi" are "Multiple Myeloma" (30 trials), "Ulcerative Colitis" (16 trials), "Heart Failure" (12 trials), "Crohn's Disease" (11 trials) and "Crohn Disease" (10 trials). Many other conditions were trialed in "Policlinico S. Orsola Malpighi" in a lesser frequency.

Most popular intervention types in "Policlinico S. Orsola Malpighi" are "Drug" (427 trials), "Other" (77 trials), "Device" (66 trials), "Procedure" (29 trials) and "Biological" (17 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (98 trials), "Dexamethasone" (20 trials), "Rituximab" (19 trials), "Azacitidine" (12 trials) and "Gemcitabine" (11 trials). Other intervention names were less common.

The vast majority of trials in "Policlinico S. Orsola Malpighi" are 580 trials for "All" genders, 39 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are 225 active trials in "Policlinico S. Orsola Malpighi". 2 are not yet recruiting, 120 are recruiting, 100 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 263 completed trials in Policlinico S. Orsola Malpighi, 2 suspended trials, and 61 terminated clinical trials to date.

Out of the total trials that were conducted in Policlinico S. Orsola Malpighi, 49 "Phase 1" clinical trials were conducted, 149 "Phase 2" clinical trials and 242 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 34 trials, and there were also 64 trials that are defined as “Not Applicable".

Policlinico S. Orsola Malpighi has several departments that took part in Clinical trials: "Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica" - 22 trials, "Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii" - 9 trials, "UNI DEGLI STUDI - POLICLINICA S. ORSOLA; Dipartimento Malattie dell'Apparato Digerente e Medicina In" - 4 trials, "Unità Operativa di Medicina del Lavoro AOU Sant'Orsola-Malpighi" - 2 trials